Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Amgen (NASDAQ:AMGN) reported Q1 2026 results: total revenue $8.6B, +6% YoY, product sales $8.218B (+4%), GAAP EPS $3.34 (+4%), and non-GAAP EPS $5.15 (+5%).
GAAP operating margin rose to 32.4%; non-GAAP margin was 45.3%. Free cash flow was $1.5B. Full-year 2026 guidance: revenue $37.1B–$38.5B, GAAP EPS $15.62–$17.10, non-GAAP EPS $21.70–$23.10; share repurchases not to exceed $3.0B.
Amgen (NASDAQ:AMGN) will report first quarter 2026 financial results on Thursday, April 30, 2026, after the U.S. market close. A conference call with management, including CEO Robert A. Bradway, will follow at 4:30 p.m. ET.
Live audio will be webcast on Amgen's investor site and archived for at least 90 days. Presentation times and webcast links are listed on Amgen's Investor Relations Events Calendar.
Amgen (NASDAQ:AMGN) announced the retirement of David M. Reese, executive vice president and Chief Technology Officer, effective June 30, 2026. The company will implement organizational changes on June 1, 2026 to deepen integration of biology, data science, and AI across R&D and commercial functions.
James Bradner will lead R&D, Artificial Intelligence and Data; Sean Bruich becomes senior vice president, Chief Technology Officer; Murdo Gordon is executive vice president, Amgen Global Markets and Policy; Paul Burton remains chief medical officer.
Amgen (NASDAQ: AMGN) announced positive topline Phase 3 results for subcutaneous TEPEZZA (teprotumumab-trbw) delivered via an on-body injector in adults with moderate-to-severe active Thyroid Eye Disease (TED).
The trial met its primary endpoint with a 76.7% proptosis response vs. 19.6% placebo and a mean proptosis reduction of -3.17 mm vs. -0.80 mm placebo at week 24 (both p<0.0001). Safety was consistent with IV TEPEZZA; common adverse events (≥10%) included muscle spasms, tinnitus, weight decrease, ear discomfort, nausea and diarrhea.
Zai Lab and Amgen (NASDAQ: AMGN) announced a global clinical trial collaboration to test Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan (zoci), combined with Amgen’s FDA-approved Bispecific T-cell Engager IMDELLTRA® in extensive-stage small cell lung cancer (ES-SCLC).
Amgen will sponsor and lead a global Phase 1b study to evaluate safety and efficacy; Zai Lab will retain full ownership of zoci and supply the study drug. Prior Phase 1/2 data showed high response rates and strong intracranial activity for zoci.
Amgen (NASDAQ:AMGN) reported that Repatha (evolocumab) reduced first major adverse cardiovascular events by 31% in a high-risk primary prevention subgroup from VESALIUS-CV.
The analysis (3,655 patients with diabetes, median 4.8 years) showed median LDL-C 44 mg/dL at 96 weeks versus 105 mg/dL for placebo; results were presented at ACC and published in JAMA.
Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026 at 9:20 a.m. ET. Peter Griffith, CFO, and Jasper van Grunsven, SVP of Rare Disease, will take part in a fireside chat. The event will be webcast live and archived for at least 90 days.
The webcast will be available to media, investors, and the public via Amgen's Investor Relations Events Calendar and archived on Amgen's website for replay.
Amgen (NASDAQ:AMGN) announced a $2.52 per share cash dividend for the second quarter of 2026. The Board declared the dividend on March 4, 2026, payable on June 5, 2026 to shareholders of record as of May 15, 2026.
Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026. Senior VPs Kave Niksefat (Global Marketing and Access) and Justin Claeys (Finance) will speak.
The presentation will be webcast live and archived for at least 90 days on Amgen's Investor Relations events calendar and webcast page, available to media, investors and the public.
Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit on Wednesday, Feb. 18, 2026 at 12:15 p.m. PT. Jean-Charles Soria, senior vice president of oncology within global development, will deliver the presentation.
The presentation will be webcast live and archived for at least 90 days on Amgen's investor website, with timing and links listed on the Investor Relations Events Calendar.